MORDOR II: Persistence of Benefit of Azithromycin for Childhood Mortality

Background. MORDOR I found that 2 years of biannual mass azithromycin administration reduced post-neonatal childhood mortality by 18% in Niger. Over time, this benefit could increase with each distribution or wane due to antibiotic resistance. Here in MORDOR II, we treated communities in both arms f...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:N Engl J Med
Main Authors: Keenan, Jeremy D., Arzika, Ahmed M., Maliki, Ramatou, Boubacar, Nameywa, Elh Adamou, Sanoussi, Moussa Ali, Maria, Cook, Catherine, Lebas, Elodie, Lin, Ying, Ray, Kathryn J., O’Brien, Kieran S., Doan, Thuy, Oldenburg, Catherine E., Callahan, E. Kelly, Emerson, Paul M., Porco, Travis C., Lietman, Thomas M.
Format: Artigo
Jezik:Inglês
Izdano: Massachusetts Medical Society 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512890/
https://ncbi.nlm.nih.gov/pubmed/31167050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1817213
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki